$SNY news
The latest SNY stock news: headlines, filings, AI summaries and sentiment for $SNY, updated around the clock.
- Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
- Novavax Reports Q3 2026 Revenue of $68.3 Million and Raises Annual Guidance
- Nurix Therapeutics Shares Decline Following Sanofi's Decision to Discontinue Inflammatory Disease Drug Studies
- Recursion Pharmaceuticals Reports Q3 Revenue Beat Amid GAAP EPS Miss
- Sanofi Reports Strong Q3 2026 Results Driven by Dupixent and Upgraded Full-Year Guidance
- Regeneron Reports 36% Year-Over-Year Revenue Growth in Q3 2026
- Regeneron Forecasts Mid-Teens R&D Expense Growth for 2027 and $1B Sanofi Payment in Q4
- Regeneron Pharmaceuticals Shares Reach 52-Week High Following Strong Q3 Results
- Regeneron Reports Strong Q3 2026 Results Driven by Sanofi Collaboration and Libtayo Growth
- Regeneron Pharmaceuticals Shares Rise Following Q3 Revenue Beat
- Sanofi Raises 2026 Profit Outlook Following Strong Dupixent Sales
- Sanofi Exceeds Q3 Earnings Estimates and Raises FY26 Financial Outlook
- Sanofi Scheduled to Report Q3 2026 Earnings on October 30
- DBV Technologies Submits VIASKIN Peanut BLA and Reports Q3 2026 Financial Results
- Regeneron's Future May Depend on Dupixent Amid Eylea Sales Decline
- Sanofi Avoids EU Fine Over Claims About Rival Flu Vaccine
- Regeneron Announces Earnings Impact from Expanded Collaboration with Sanofi
- Pfizer, Sanofi, and Novartis Highlight Key Healthcare News of the Week
- Regeneron Reports Mixed Results in Ovarian Cancer Therapy Trial
- Sanofi Agrees to Pay Up to $8 Billion for Expanded Long-Acting Drug Pipeline
- Regeneron Reports Strong Performance from EYLEA HD, Dupixent Growth, and Upcoming Pipeline Catalysts
- AstraZeneca's Tozorakimab Shows Strong Results in COPD Trials
- North Immunology to go public via reverse merger with Aethlon Medical
- Cheplapharm Acquires Portfolio of 20 Medicines and Three Manufacturing Sites from Sanofi
- VTEX Reports Improved Profitability Amid Slowing Growth
- AstraZeneca's COPD Drug Shows Strong Trial Results and Blockbuster Potential
- Owkin partners with Boehringer Ingelheim for AI-driven drug discovery
- FDA Approves Regeneron's Rare-Disease Drug Pasatru Despite Small Market Potential
- Novavax receives global approvals for updated Nuvaxovid COVID-19 vaccine
- Sanofi Aims to Rebuild Trust with Regeneron; Apnimed's Upsized IPO Adds Momentum
- Regeneron Pharmaceuticals Reports Strong Q2 Growth Driven by Dupixent, EYLEA HD
- Regeneron Reports Strong Q2 Earnings with Revenue Growth and Record Sales
- Regeneron Exceeds Q2 Earnings and Revenue Expectations Driven by Dupixent Growth
- Sanofi Raises Full-Year Outlook Amid Strong Q2 Performance Driven by Dupixent Growth
- Regeneron Exceeds Quarterly Estimates, Driven by Strong Sales of Eczema Drug Dupixent
- Sanofi Exceeds Q2 Earnings Expectations Driven by Strong Dupixent Sales
- Sanofi Exceeds Earnings and Revenue Estimates, Raises FY26 Outlook
- Eli Lilly and Sanofi Backed Scribe Therapeutics Surges Nearly 50% in Upsized IPO
- Sanofi receives FDA approval for subcutaneous version of multiple myeloma drug Sarclisa
- BofA Analyst Comments on Sanofi's Leadership Change
- Deutsche Bank Lowers Price Target for Sanofi to EUR95
- NVIDIA Supports France's Expansion of Artificial Intelligence Ecosystem
- AbbVie Announces $10.9 Billion Acquisition of Apogee Therapeutics
- EU Commission Launches Antitrust Probe into Sanofi's Flu Vaccine Marketing
- EU Launches Antitrust Investigation into Sanofi Over Alleged Disparagement of Competitor's Flu Vaccine
- MacroGenics Receives $24.5M Milestone Payment from Sanofi Following Tzield Approval
- Sanofi Halts Phase 3 Trial of Riliprubart in Rare Nerve Disease Due to Efficacy Concerns
- PatentVest Report Analyzes Triple-Agonist Obesity Drug Development and Patent Strategies
- Recursion Pharmaceuticals Reports Q1 2026 Earnings and Provides Business Update
- Novavax Q3 2025 Earnings Report Shows Strategic Shift and Revenue Decline